Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab

• Váldodahkkit: Jared Liu (Dahkki), Hsin-Wen Chang (Dahkki), Robby Grewal (Dahkki), Daniel D. Cummins (Dahkki), Audrey Bui (Dahkki), Kristen M. Beck (Dahkki), Sahil Sekhon (Dahkki), Di Yan (Dahkki), Zhi-Ming Huang (Dahkki), Timothy H. Schmidt (Dahkki), Eric J. Yang (Dahkki), Isabelle M. Sanchez (Dahkki), Mio Nakamura (Dahkki), Shrishti Bhattarai (Dahkki), Quinn Thibodeaux (Dahkki), Richard Ahn (Dahkki), Mariela Pauli (Dahkki), Tina Bhutani (Dahkki), Michael D. Rosenblum (Dahkki), Wilson Liao (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2022-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The IL-17A inhibitor secukinumab is efficacious for the treatment of psoriasis. To better understand its mechanism of action, we investigated its impact on psoriatic lesions from 15 patients with moderate-to-severe plaque psoriasis undergoing secukinumab treatment. We characterized the longitudinal...